Search Results

Cyclosporine

• Source: Funk & Wagnalls New World Encyclopedia. 2018, 1p.

Record details

The evolution of cyclosporine treatments for treatment of ocular surface diseases.

• Authors : Flts A; Rowan-Virtua School of Medicine, Stratford, New Jersey.; Medina R

Subjects: Cyclosporine*/Cyclosporine*/Cyclosporine*/therapeutic use ; Cyclosporine*/Cyclosporine*/Cyclosporine*/administration & dosage; Humans

• Source: Current opinion in allergy and clinical immunology [Curr Opin Allergy Clin Immunol] 2024 Oct 01; Vol. 24 (5), pp. 360-367. Date of Electronic Publication: 2024 Jul 24.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 100936359 Publication Model: Print-Electronic Cited Medium:

Record details

Cyclosporine A improves the binding of mouse embryos to fibronectin.

• Authors : Shengnan T; Hainan Provincial Key Laboratory for Human Reproductive Medicine and Genetic Research, The First Affiliated Hospital of Hainan Medical University, Hainan Medical University, Haikou, China.; Hainan Medical University, Haikou, China.

Subjects: Fibronectins*/Fibronectins*/Fibronectins*/metabolism ; Cyclosporine*/Cyclosporine*/Cyclosporine*/pharmacology; Animals

• Source: The journal of obstetrics and gynaecology research [J Obstet Gynaecol Res] 2024 Oct; Vol. 50 (10), pp. 1891-1901. Date of Electronic Publication: 2024 Aug 27.Publisher: Wiley on behalf of the Japan Society of Obstetrics and Gynecology] Country of Publication: Australia NLM ID: 9612761 Publication Model:

Record details

Unpredictable Cyclosporine Clearance in a Korean Patient With Aplastic Anemia With Adverse Effects: A Case Study.

• Authors : Shihmanter R; Clinical Pharmacology Unit, Kaplan Medical Center, Rehovot.; Hebrew University Hadassah Medical School, Jerusalem

Subjects: Anemia, Aplastic* ; Cyclosporine*/Cyclosporine*/Cyclosporine*/therapeutic use ; Cyclosporine*/Cyclosporine*/Cyclosporine*/adverse effects

• Source: Therapeutic drug monitoring [Ther Drug Monit] 2024 Oct 01; Vol. 46 (5), pp. 563-566. Date of Electronic Publication: 2024 Aug 20.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 7909660 Publication Model: Print-Electronic Cited Medium:

Record details

Risk factors for cyclosporine A-associated hypertension in dermatology.

• Authors : Lee SR; Department of Dermatology, Seoul Metropolitan Government-Seoul National University (SMG-SNU) Boramae Medical Center, Seoul, South Korea.; Oh S

Subjects: Cyclosporine*/Cyclosporine*/Cyclosporine*/adverse effects ; Hypertension*/Hypertension*/Hypertension*/chemically induced; Humans

• Source: International journal of dermatology [Int J Dermatol] 2024 Sep; Vol. 63 (9), pp. e209-e212. Date of Electronic Publication: 2024 Jun 10.Publisher: Blackwell Science Country of Publication: England NLM ID: 0243704 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Effects of combined intense pulsed light and cyclosporine 0.05% eyedrops in ocular surface matrix metalloproteinase-9 levels in patients with moderate-to-severe MGD.

• Authors : Jeon YY; Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, South Korea.; Bae S

Subjects: Matrix Metalloproteinase 9*/Matrix Metalloproteinase 9*/Matrix Metalloproteinase 9*/metabolism ; Cyclosporine*/Cyclosporine*/Cyclosporine*/administration & dosage ; Ophthalmic Solutions*/Ophthalmic Solutions*/Ophthalmic Solutions*/administration & dosage

• Source: Lasers in medical science [Lasers Med Sci] 2024 Aug 01; Vol. 39 (1), pp. 203. Date of Electronic Publication: 2024 Aug 01.Publisher: Springer Country of Publication: England NLM ID: 8611515 Publication Model: Electronic Cited Medium: Internet ISSN: 1435-604X

Record details

Immunosuppression with cyclosporine versus tacrolimus shows distinctive nephrotoxicity profiles within renal compartments.

• Authors : Demirci H; Institute of Functional Anatomy, Charité, Universitätsmedizin Berlin, Berlin, Germany.; Department of Cell- and Neurobiology, Charité, Universitätsmedizin Berlin, Berlin, Germany.

Subjects: Tacrolimus*/Tacrolimus*/Tacrolimus*/pharmacology ; Cyclosporine*/Cyclosporine*/Cyclosporine*/adverse effects ; Cyclosporine*/Cyclosporine*/Cyclosporine*/toxicity

• Source: Acta physiologica (Oxford, England) [Acta Physiol (Oxf)] 2024 Aug; Vol. 240 (8), pp. e14190. Date of Electronic Publication: 2024 Jun 17.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101262545 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Synergistic antifungal activity against Candida albicans between voriconazole and cyclosporine a loaded in polymeric nanoparticles.

• Authors : Martín V; Department of Physical Chemistry, University of Seville, C/Profesor García González 1, Seville 41012, Spain.; de la Haba RR

Subjects: Voriconazole*/Voriconazole*/Voriconazole*/administration & dosage ; Voriconazole*/Voriconazole*/Voriconazole*/pharmacology ; Voriconazole*/Voriconazole*/Voriconazole*/chemistry

• Source: International journal of pharmaceutics [Int J Pharm] 2024 Oct 25; Vol. 664, pp. 124593. Date of Electronic Publication: 2024 Aug 19.Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium:

Record details

Post-transplantation cyclophosphamide and cyclosporine A versus methotrexate and cyclosporine A for graft-versus-host disease prophylaxis after allogeneic peripheral stem cell transplantation in adult acute myeloid leukemia patients.

• Authors : Sharaf El-Deen MO; Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.; Soliman MM

Subjects: Graft vs Host Disease*/Graft vs Host Disease*/Graft vs Host Disease*/prevention & control ; Cyclosporine*/Cyclosporine*/Cyclosporine*/therapeutic use ; Cyclosporine*/Cyclosporine*/Cyclosporine*/administration & dosage

• Source: Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2024 Oct; Vol. 491, pp. 117071. Date of Electronic Publication: 2024 Aug 17.Publisher: Academic Press Country of Publication: United States NLM ID: 0416575 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Effectiveness of cyclosporine nanoemulsion eye drops in patients with mild-to-moderate dry eyes: objective and subjective evaluation.

• Authors : Moon SY; Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.; Chung HS

Subjects: Dry Eye Syndromes*/Dry Eye Syndromes*/Dry Eye Syndromes*/drug therapy ; Dry Eye Syndromes*/Dry Eye Syndromes*/Dry Eye Syndromes*/physiopathology ; Cyclosporine*/Cyclosporine*/Cyclosporine*/administration & dosage

• Source: BMC ophthalmology [BMC Ophthalmol] 2024 Sep 09; Vol. 24 (1), pp. 401. Date of Electronic Publication: 2024 Sep 09.Publisher: BioMed Central Country of Publication: England NLM ID: 100967802 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2415

Record details